Advertisement

Clinical Drug Investigation

, Volume 39, Issue 12, pp 1195–1203 | Cite as

Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment

  • Nai-Lun Yeh
  • Che-Yuan Hsu
  • Tsen-Fang Tsai
  • Hsien-Yi ChiuEmail author
Original Research Article

Abstract

Background and Objective

Immunotherapy could change the complex host-microbial interactions. We aimed to investigate the dynamics of gut microbiome in response to secukinumab [an interleukin (IL)-17 inhibitor] and ustekinumab (an IL-12/23 inhibitor) therapy and its association with treatment response in psoriasis.

Methods

This observational, longitudinal study collected a total of 114 fecal samples from 12 healthy controls and 34 patients with psoriasis at baseline and 3 and 6 months after secukinumab (n = 24) or ustekinumab treatment (n = 10) and gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA.

Results

Secukinumab treatment causes more profound alterations in gut microbiome, including increases in the relative abundance of phylum Proteobacteria and decreases in Bacteroidetes and Firmicutes, than ustekinumab treatment. The relative abundance of family Pseudomonadaceae, family Enterobacteriaceae and order Pseudomonadales also increased significantly following secukinumab therapy. In contrast, there was no significant change in gut microbiome composition following ustekinumab treatment, and only genus Coprococcus significantly increased after 6 months of ustekinumab therapy. Moreover, we observed significant differences in baseline gut microbiome between responders and non-responders to secukinumab treatment.

Conclusion

These results indicate that gut microbiome is altered differently after anti-IL17 and anti-IL12/23 treatment. Secukinumab (anti-IL17) therapy is associated with distinct and more profound gut microbiome shifts than ustekinumab therapy (anti-IL 12/23) in patients with psoriasis. Moreover, gut microbiome would serve as potential biomarkers of response to secukinumab treatment.

Notes

Acknowledgements

The authors would like to thank Dr. Yu-Lun Kuo at BIOTOOLS Co., Ltd., in Taiwan for the kind support in the analysis of NGS data. All authors have significantly contributed to the manuscript and all agree with its contents. Authors do not have any relevant financial interests in the findings from this manuscript.

Compliance with Ethical Standards

Funding

This study was supported by the National Taiwan University Hospital, Hsinchu Branch (106-HCH028 and 107-HCH009) and the Ministry of Science and Technology, Taiwan (formerly, the National Science Council; Grant Numbers, MOST 107-2314-B-002-259-MY3).

Conflict of interest

Dr. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, Boehringer Ingelheim, Celgene, Eli-Lilly, Galderma, GSK, Janssen-Cilag, Leo Pharma, Merck-Serono, Novartis International AG, and Pfizer Inc. Dr. Hsien-Yi Chiu have received speaking fees from AbbVie, Eli-Lilly, Novartis Pharmaceuticals Corporation, Janssen-Cilag Pharmaceutica, and Pfizer Limited. Other authors have no conflicts of interest to declare.

Ethics approval and informed consent

The study protocol was reviewed and approved by the local Institutional Review Board of the National Taiwan University Hospital, Hsinchu branch (105-069-E) and informed consent had been obtained from each patient.

Supplementary material

40261_2019_849_MOESM1_ESM.pdf (1.3 mb)
Supplementary material 1 (PDF 1287 kb)

References

  1. 1.
    Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485–98.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Stepankova R, Powrie F, Kofronova O, Kozakova H, Hudcovic T, Hrncir T, et al. Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis. 2007;13:1202–11.PubMedGoogle Scholar
  3. 3.
    Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282–6.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453:620–5.PubMedGoogle Scholar
  5. 5.
    Majamaa H, Isolauri E. Evaluation of the gut mucosal barrier: evidence for increased antigen transfer in children with atopic eczema. J Allergy Clin Immunol. 1996;97:985–90.PubMedGoogle Scholar
  6. 6.
    Mattozzi C, Richetta AG, Cantisani C, Macaluso L, Calvieri S. Psoriasis: new insight about pathogenesis, role of barrier organ integrity, NLR/CATERPILLER family genes and microbial flora. J Dermatol. 2012;39:752–60.PubMedGoogle Scholar
  7. 7.
    Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W. Diet and psoriasis, part II: celiac disease and role of a gluten-free diet. J Am Acad Dermatol. 2014;71:350–8.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol. 2006;176:7104–11.PubMedGoogle Scholar
  9. 9.
    Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today. 1995;16:145–9.PubMedGoogle Scholar
  10. 10.
    Yan D, Issa N, Afifi L, Jeon C, Chang HW, Liao W. The role of the skin and gut microbiome in psoriatic disease. Curr Dermatol Rep. 2017;6:94–103.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–60.PubMedGoogle Scholar
  12. 12.
    Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.PubMedGoogle Scholar
  13. 13.
    Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–700.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Fobelo Lozano MJ, Serrano Gimenez R, Castro Fernandez M. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohns Colitis. 2018.  https://doi.org/10.1093/ecco-jcc/jjy063(epub ahead of print).CrossRefPubMedGoogle Scholar
  15. 15.
    Martin R, Henley JB, Sarrazin P, Seite S. Skin microbiome in patients with psoriasis before and after balneotherapy at the thermal care center of La Roche-Posay. J Drugs Dermatol. 2015;14:1400–5.PubMedGoogle Scholar
  16. 16.
    Assarsson M, Duvetorp A, Dienus O, Soderman J, Seifert O. Significant changes in the skin microbiome in patients with chronic plaque psoriasis after treatment with narrowband ultraviolet B. Acta Derm Venereol. 2018;98:428–36.PubMedGoogle Scholar
  17. 17.
    Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, et al. Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial. J Invest Dermatol. 2018;138:1973–81.PubMedGoogle Scholar
  18. 18.
    Chiu HY, Hui RC, Huang YH, Huang RY, Chen KL, Tsai YC, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98:829–34.PubMedGoogle Scholar
  19. 19.
    Chiu HY, Chu TW, Cheng YP, Tsai TF. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10:e0142930.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Fierer N, Lauber CL, Zhou N, McDonald D, Costello EK, Knight R. Forensic identification using skin bacterial communities. Proc Natl Acad Sci. 2010;107:6477–81.PubMedGoogle Scholar
  21. 21.
    Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012;6:1621–4.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460–1.PubMedGoogle Scholar
  23. 23.
    Paulson JN, Stine OC, Bravo HC, Pop M. Differential abundance analysis for microbial marker-gene surveys. Nat Methods. 2013;10:1200–2.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814–21.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014;42:D199–205.PubMedGoogle Scholar
  27. 27.
    Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103.PubMedGoogle Scholar
  28. 28.
    Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7.PubMedGoogle Scholar
  29. 29.
    Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1:31.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch Dermatol Res. 2012;304:15–22.PubMedGoogle Scholar
  31. 31.
    Drago L, De Grandi R, Altomare G, Pigatto P, Rossi O, Toscano M. Skin microbiota of first cousins affected by psoriasis and atopic dermatitis. Clin Mol Allergy. 2016;14:2.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Ramirez-Bosca A, Navarro-Lopez V, Martinez-Andres A, Such J, Frances R, Horga de la Parte J, et al. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151:670–1.PubMedGoogle Scholar
  33. 33.
    Zakostelska Z, Malkova J, Klimesova K, Rossmann P, Hornova M, Novosadova I, et al. Intestinal microbiota promotes psoriasis-like skin inflammation by enhancing Th17 response. PLoS One. 2016;11:e0159539.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Zhang Z, Liu L, Tang H, Jiao W, Zeng S, Xu Y, et al. Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice. Am J Transplant. 2018;18:1646–56.PubMedGoogle Scholar
  35. 35.
    Huang EY, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:963–72.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Yang J, Liu KX, Qu JM, Wang XD. The changes induced by cyclophosphamide in intestinal barrier and microflora in mice. Eur J Pharmacol. 2013;714:120–4.PubMedGoogle Scholar
  37. 37.
    Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl. 2012;1:15.Google Scholar
  38. 38.
    Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe. 2010;8:292–300.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CH, Stanners CP, et al. Crohn’s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med. 2009;206:2179–89.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Carvalho FA, Koren O, Goodrich JK, Johansson ME, Nalbantoglu I, Aitken JD, et al. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe. 2012;12:139–52.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569–73.PubMedGoogle Scholar
  42. 42.
    Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–50.PubMedGoogle Scholar
  43. 43.
    Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion. 2016;93:59–65.PubMedGoogle Scholar
  44. 44.
    Wagner J, Short K, Catto-Smith AG, Cameron DJ, Bishop RF, Kirkwood CD. Identification and characterisation of Pseudomonas 16S ribosomal DNA from ileal biopsies of children with Crohn’s disease. PLoS One. 2008;3:e3578.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.PubMedPubMedCentralGoogle Scholar
  46. 46.
    von Schillde MA, Hormannsperger G, Weiher M, Alpert CA, Hahne H, Bauerl C, et al. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe. 2012;11:387–96.Google Scholar
  47. 47.
    Cinova J, De Palma G, Stepankova R, Kofronova O, Kverka M, Sanz Y, et al. Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PLoS One. 2011;6:e16169.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Chen L, Wang W, Zhou R, Ng SC, Li J, Huang M, et al. Characteristics of fecal and mucosa-associated microbiota in Chinese patients with inflammatory bowel disease. Medicine (Baltimore). 2014;93:e51.Google Scholar
  49. 49.
    Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83.PubMedGoogle Scholar
  50. 50.
    Kanauchi O, Fukuda M, Matsumoto Y, Ishii S, Ozawa T, Shimizu M, et al. Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity. World J Gastroenterol. 2006;12:1071–7.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, et al. Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn’s disease patients. MBio. 2018;9 (pii: e02120-17).Google Scholar
  52. 52.
    Zhou Y, Xu ZZ, He Y, Yang Y, Liu L, Lin Q, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3 (pii: e00188-17).Google Scholar
  53. 53.
    Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci. 2007;104:13780–5.PubMedGoogle Scholar
  54. 54.
    Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1–10.PubMedGoogle Scholar
  55. 55.
    Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67:1716–25.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–4.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Community and Family MedicineNational Taiwan University Hospital Hsinchu BranchHsinchuTaiwan
  2. 2.Department of DermatologyNational Taiwan University Hospital Hsinchu BranchHsinchuTaiwan
  3. 3.Department of DermatologyNational Taiwan University HospitalTaipeiTaiwan
  4. 4.Department of Dermatology, College of MedicineNational Taiwan UniversityTaipeiTaiwan
  5. 5.Institute of Biomedical Engineering, College of Medicine and College of EngineeringNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations